Ruichen Kangda

Rui Chen Kangda biomedical

Ruichen Kangda Biomedicine (Wuhan) Co., Ltd. was founded in Optics Valley Biomedical Park, East Lake New Technology Development Zone, East Lake National Independent Innovation Demonstration Zone, Wuhan.

We have a high-quality and high-level R&D team led by many senior overseas returnees.

Through continuous learning and hard work, we improve our research and development capabilities and efficiency, and provide customers with more efficient and faster chemical services.

Company profile

Culture

HR

Honours

Product center

NEWS CENTER

2020

10 -15

Based on the long-term growth of the pharmaceutical industry, GF Fund will deploy the second actively managed pharmaceutical theme fund on October 13th-GF Pharmaceutical Health Mix.

2020

10 -15

Today, Hua Medicine announced that after the review of the Drug Marketing Authorization Holder (MAH) system and on-site verification, the company has obtained the world’s first innovative drug under research, dorzagliatin (dorzagliatin) issued by the Shanghai Drug Administration. "Drug Production License".

2020

10 -15

Biohaven Pharmaceutical announced today that the US FDA has accepted the company's recent supplementary new drug application (sNDA) for the preventive treatment of migraine for Nurtec ODT (rimegepant), and it is expected to respond in the second quarter of next year. Nurtec is a small molecule CGRP receptor inhibitor. The press release pointed out that Nurtec is expected to become a unique treatment that can be used for both preventive treatment and acute treatment of migraine.

2020

10 -15

In-depth focus on industrial policies, global pharmaceutical R&D trends, and investment and financing trends, comprehensively discuss global pharmaceutical innovation development trends, and discuss new developments in biomedical investment cooperation.

2020

10 -15

Today, the American biotechnology company Replimune announced that it will announce the Phase I clinical progress of two oncolytic virus (OV) therapies at this year’s SITC annual meeting. The first-generation HSV oncolytic virus RP1 combined with Opdivo produced a higher response rate in several skin cancers.
Ruichen Kangda

TEL:13564855401

ADD:S805-806, Zone B, Free Trade Biological Innovation Port, No. 777 Guanggu 3rd Road, Donghu New Technology Development Zone, Wuhan, Hubei Province

E-mail:liujun@rcchemtec.cn

Website:http://www.rcchemtec.cn

Ruichen Kangda

Mobile site

Copyright © 2020 Ruichen Kangda Biomedical (Wuhan) Co., Ltd.

Technical surpport by www.300.cn

鄂ICP备2020011351号